Thymalfasin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
== Beyond plant disease == Potyvirus RNA codes for at least seven different proteins. One of them is a protease. The TEV protease is a highly site-specific protease that biochemists have used to their advantage to create a protein purification system by incorporating TEV protease's recognition site into protein purification tags. A gene construct is created containing the protein of interest fused to a TEV protease recognition site, followed by an affinity tag, such as a polyhistidine-tag. Following affinity chromatography, the purified protein is then treated with TEV protease. TEV protease cleaves at its recognition site, removing the affinity tag. This allows for affinity purification of proteins that are not well-behaved when fused to protein tags.
Neuromodulation is "the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body". It is carried out to normalize – or modulate – nervous tissue function. Neuromodulation is an evolving therapy that can involve a range of electromagnetic stimuli, such as a magnetic field (rTMS), an electric current, or a drug delivered directly into the subdural space (intrathecal drug delivery). Emerging applications involve targeted introduction of genes or gene regulators and light (optogenetics), and by 2014, these had been at minimum demonstrated in mammalian models, or first-in-human data had been acquired. The most clinical experience has been with electrical stimulation. Neurotherapy, in modern use, is a synonym for neuromodulation. While neurotherapy may have a broader meaning, its modern definition focuses exclusively on technological methods that exert an energy-based effect on the development of a balanced nervous system in order to address symptom control and cure several conditions. Neurotherapy is a medical treatment that implements systemic targeted delivery of an energy stimulus or chemical agents to a specific neurological zone in the body to alter neuronal activity and stimulate neuroplasticity in a way that develops (or balances) a nervous system in order to treat different diseases, restore and/or to improve patients' physical strength, cognitive functions, and overall health.
=== Nanomaterials === Nanomaterials include carbon-based materials, metal oxides, metals, and quantum dots. Nanomaterials can enter the environment during their manufacturing, consumer use, or disposal. Due to their small size, nanomaterials behave differently than larger particles. They have a high surface area to volume ratio, which can lead to increased reactivity and the potential to transport throughout the environment. Nanomaterials are challenging to detect and monitor due to their size and the absence of standardized methods for measuring their presence and concentration in various media.
Sources: en.wikipedia.org
In this instance reversal of paralysis will not occur until the damaged terminal axons at the neuromuscular junction have recovered, this may take days or weeks. The drug may also be used for reversal of neuromuscular blockade at the end of a surgical procedure.
=== The Final Hours of Portal 2 === The Final Hours of Portal 2 is a digital book written and created by Geoff Keighley released on May 17, 2011. This digital book gives insight on the creation of Portal 2. Keighley had previously worked as an editor at GameSpot, writing several 10,000-word "Final Hours" pieces on various games where he visited the studios during the late development phases to document the creation of the game. One piece, "The Final Hours of Half-Life 2", allowed Keighley to interact with Valve during 2003 and 2004 and talk with the staff as they completed work on Half-Life 2. Keighley wanted to recreate a similar work for Portal 2, with focus on making it an interactive work for the iPad. Keighley was granted "fly on the wall" access to Valve when Portal 2 was being produced. The initial iPad release was written by Keighley with work by Joe Zeff Design, a studio that had also produced digital applications for Time magazine. The interactive work provides movie clips and short applications to demonstrate the various mechanics of the game and stages of the game's development. The work was later ported into a non-interactive eBook, and into an application with the same iPad interactivity on the Steam platform. With the iPad and Steam version, Keighley is able to offer live updates to the work; upon release of the "Peer Review" downloadable content pack, the work was updated with an additional chapter discussing the creation of the new content and what new features players could expect in the future from Portal 2.
== Pharmacokinetics == Trelagliptin's uniquely designed structure enhances its chemical stability and resistance to metabolic degradation. It binds strongly to the DPP-4 enzyme, with a slow dissociation rate (~30 minutes), compared to sitagliptin (3.5 min) and vildagliptin (<2 min). This prolonged binding contributes to its sustained DPP-4 inhibition. Trelagliptin has a long elimination half-life of approximately 54.3 hours. A 100 mg once-weekly dose maintained 77.4% DPP-4 inhibition 7 days post-dose. The drug reaches steady-state plasma levels (20.00–21.60 ng/mL) by week 4. These properties support its effective once-weekly dosing regimen.
Sources: en.wikipedia.org
== See also == Alternative abiogenesis scenarios – Proposed alternative scenarios related to abiogenesis Autopoiesis – System capable of producing itself Formamide-based prebiotic chemistry – Scientific hypothesis that life originated from formamide precursors Proto-metabolism – Chemical reactions which turn into modern metabolism GADV-protein world hypothesis – Hypothetical stage of abiogenesis Genetic recombination – Shuffling of genetic material Shadow biosphere – Hypothetical biosphere of Earth Manganese metallic nodules – Mineral concretion found on the sea bottomPages displaying short descriptions of redirect targets Virus world hypothesis – Theory that viruses predate cellular life
== Medical uses == Olanzapine/fluoxetine was approved by the U.S. Food and Drug Administration (FDA) to treat the depressive episodes of bipolar I disorder in 2003. In 2009, it was granted approval for the treatment of treatment-resistant depression. Olanzapine/fluoxetine, or other antidepressant/antipsychotic combinations, are sometimes prescribed off-label for anxiety disorders, eating disorders, obsessive–compulsive disorder (OCD), and posttraumatic stress disorder (PTSD).
== External links == Clinical trial number NCT02257567 for "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma" at ClinicalTrials.gov Clinical trial number NCT03274492 for "A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)" at ClinicalTrials.gov
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.